These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 35365045)

  • 1. Five-year disease-free survival of Epstein-Barr virus-associated locoregionally advanced undifferentiated nasopharyngeal carcinoma patients treated with chemo-radiotherapy: a case report.
    Wang N; Wang H; Jiang H; Bi Y; Zhao Y; He X; Cao F; Yuan Y
    Ann Palliat Med; 2022 Mar; 11(3):1147-1152. PubMed ID: 35365045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can Epstein-Barr virus-deoxyribonucleic acid load after induction chemotherapy combined with American Joint Committee on Cancer stage determine the chemotherapy intensity of locally advanced nasopharyngeal carcinoma?
    Zhang Q; Peng ZW; Gu ZS; Wang Y; He F; Zhao WB; Luo W; Mei YY
    Cancer Med; 2023 Jan; 12(1):223-235. PubMed ID: 35674137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis.
    Jin YN; Qiang MY; Wang Y; Lin YJ; Jiang RW; Cao WW; Zhang WJ; Wang SY; Zhang HY; Yao JJ
    Cancer Immunol Immunother; 2024 May; 73(7):125. PubMed ID: 38733402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level.
    Liu SL; Sun XS; Xie HJ; Chen QY; Lin HX; Liang H; Liang YJ; Li XY; Yan JJ; Lin C; Yang ZC; Guo SS; Liu LT; Tang QN; Du YY; Tang LQ; Guo L; Mai HQ
    BMC Cancer; 2020 Feb; 20(1):89. PubMed ID: 32013967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffusion-Weighted Magnetic Resonance Imaging-Guided Dose Painting in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy Plus Concurrent Chemoradiotherapy: A Randomized, Controlled Clinical Trial.
    Fu S; Li Y; Han Y; Wang H; Chen Y; Yan O; He Q; Ma H; Liu L; Liu F
    Int J Radiat Oncol Biol Phys; 2022 May; 113(1):101-113. PubMed ID: 35074433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
    Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
    Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying optimal candidates for induction chemotherapy among stage II-IVa nasopharyngeal carcinoma based on pretreatment Epstein-Barr virus DNA and nodal maximal standard uptake values of [
    Xie HJ; Yu YF; Sun XS; Jia GD; Luo DH; Sun R; Liu LT; Guo SS; Liu SL; Chen QY; Tang LQ; Mai HQ
    Cancer Med; 2020 Dec; 9(23):8852-8863. PubMed ID: 33034945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA.
    Liang YJ; Wen DX; Luo MJ; Tang LQ; Guo SS; Wang P; Chen QY; Liu LT; Mai HQ
    Eur J Cancer; 2021 Dec; 159():133-143. PubMed ID: 34743068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.
    Chen FP; Luo YS; Chen K; Li JY; Huo LQ; Shi L; Ou-Yang Y; Cao XP
    Eur J Cancer; 2021 Jul; 151():63-71. PubMed ID: 33964573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial.
    Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J; Sun Y
    Int J Cancer; 2019 Jul; 145(1):295-305. PubMed ID: 30613964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of nivolumab with standard induction chemotherapy in children and adults with EBV-positive nasopharyngeal carcinoma : Protocol of a prospective multicenter phase 2 trial.
    Römer T; Vokuhl C; Staatz G; Mottaghy FM; Christiansen H; Eble MJ; Timmermann B; Klussmann JP; Elbracht M; Calaminus G; Zimmermann M; Brümmendorf TH; Feuchtinger T; Kerp H; Kontny U
    HNO; 2024 Jun; 72(6):423-439. PubMed ID: 38214716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
    Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J
    Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era.
    Chen WH; Tang LQ; Guo SS; Chen QY; Zhang L; Liu LT; Qian CN; Guo X; Xie D; Zeng MS; Mai HQ
    Medicine (Baltimore); 2016 Feb; 95(5):e2642. PubMed ID: 26844482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial.
    Guo SS; Yang JH; Sun XS; Liu LZ; Yang ZC; Liu LT; Liu SL; Li XY; Lv XF; Luo DH; Li JB; Liu Q; Wang P; Guo L; Mo HY; Sun R; Yang Q; Liang YJ; Jia GD; Zhao C; Chen QY; Tang LQ; Mai HQ
    Eur J Cancer; 2023 Nov; 194():113336. PubMed ID: 37801967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy.
    Lv JW; Qi ZY; Zhou GQ; He XJ; Chen YP; Mao YP; Chen L; Tang LL; Li WF; Lin AH; Ma J; Sun Y
    Cancer Sci; 2018 Mar; 109(3):751-763. PubMed ID: 29266526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.
    Yang Q; Cao SM; Guo L; Hua YJ; Huang PY; Zhang XL; Lin M; You R; Zou X; Liu YP; Xie YL; Wang ZQ; Mai HQ; Chen QY; Tang LQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Li JB; Ling L; Guo X; Hong MH; Chen MY
    Eur J Cancer; 2019 Sep; 119():87-96. PubMed ID: 31425966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma.
    Zhang J; Peng H; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
    BMC Cancer; 2018 Dec; 18(1):1276. PubMed ID: 30567511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.
    Hong RL; Hsiao CF; Ting LL; Ko JY; Wang CW; Chang JTC; Lou PJ; Wang HM; Tsai MH; Lai SC; Liu TW
    Ann Oncol; 2018 Sep; 29(9):1972-1979. PubMed ID: 30016391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining tumor response and personalized risk assessment: Potential for adaptation of concurrent chemotherapy in locoregionally advanced nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.
    Luo WJ; Zou WQ; Liang SB; Chen L; Zhou GQ; Peng H; Li WF; Liu X; Sun Y; Lin AH; Ma J; Mao YP
    Radiother Oncol; 2021 Feb; 155():56-64. PubMed ID: 33039423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoplasmic poly(A)-binding protein 1 (PABPC1) is a prognostic biomarker to predict survival in nasopharyngeal carcinoma regardless of chemoradiotherapy.
    Ling F; Xu S; Li X; Sun X; Long W
    BMC Cancer; 2023 Feb; 23(1):169. PubMed ID: 36803974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.